Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zinc & prostate cancer

This article was originally published in The Tan Sheet

Executive Summary

Chronic zinc oversupply "may play a role in prostate carcinogenesis," according to data compiled by Michael Leitzmann, MD, National Institutes of Health, et al., appearing in July 2 Journal of the National Cancer Institute. Researchers found that "compared with nonusers, men who consumed more than 100 mg per day of supplemental zinc had a relative risk of advanced prostate cancer of 2.29, and men who took supplemental zinc for ten or more years" had a relative risk of 2.37. Leitzmann et al. studied data collected from 46,974 men in the Health Professionals Follow-Up Study between 1986 and 2000. Residual confounding by supplemental calcium intake or by an unmeasured correlate of zinc supplement use could explain these findings, researchers suggest, although they recommend further investigation...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel